PubMed · 42749152
Pathway-driven target prioritisation in drug discovery.
Abstract
Genome-scale association studies and functional screens routinely implicate hundreds of candidate genes per disease, yet only a few will be clinically validated as drug targets. Choosing which to pursue is a central drug-discovery decision that depends on interpreting each candidate in its biological context. Curated pathway databases provide this context, while enrichment analysis applies it at scale, turning gene-level signals from genome-wide association, transcriptomic, proteomic and CRISPR studies into mechanistic hypotheses for prioritisation. This review examines how pathway-based methods inform target prioritisation, the databases and tools available for this purpose, and why pathway co-membership should be viewed as a starting point for validation rather than as evidence of causal involvement.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Polina Rusina, David Ochoa, Franck Rapaport, Shameer Khader, Ellen M McDonagh. 2026-09-16. Pathway-driven target prioritisation in drug discovery.. https://doi.org/10.1016/j.drudis.2026.104805
Cite the original work for its findings. Save a collection to share your selection of sources.